Placebo-Controlled Ashwagandha Trials 2020–2025: A Quantitative Review

Placebo-controlled studies published between 2020 and 2025 examined ashwagandha for stress, anxiety, sleep, cognition, fatigue and physical performance. Stress and sleep have the largest bodies of human trial data, but the studies remain heterogeneous: they use different plant parts, extraction methods, standardization markers, doses, durations and outcome scales. This review summarizes the regimens and numerical results actually reported while distinguishing modern standardized extracts from the traditional Ayurvedic root drug.

Background: What Is Ashwagandha?

Aśvagandhā (अश्वगंधा; Withania somnifera Dunal) is represented in the Ayurvedic Pharmacopoeia of India by the dried mature root. Its name is commonly associated with the root’s characteristic horse-like smell: aśva means horse and gandha means smell. The pharmacopoeial monograph records its rasa as tikta and kaṣāya, guṇa as laghu, vīrya as uṣṇa and vipāka as madhura. Its stated actions are rasāyana, balya, vājīkaraṇa and vātakaphāpaha, indicating traditional use as a rejuvenative, strength-promoting and Vāta-Kapha-alleviating drug.

The pharmacopoeial root contains alkaloids and withanolides and has a traditional powdered-root dose of 3–6 g. This dose cannot be directly converted into milligrams of a concentrated extract. Modern trials have used root extracts, combined root-and-leaf extracts and proprietary preparations with widely differing withanolide specifications. Root and leaf have different chemical profiles, so products using these plant parts should not be treated as interchangeable. “Adaptogen” is a modern pharmacological category rather than a synonym for the classical Ayurvedic term rasāyana.

Stress and Anxiety Trials

A 2014 systematic review by Pratte and colleagues located five randomized human trials of ashwagandha for anxiety or stress-related outcomes. The studies generally favored ashwagandha, but variations in populations, products, measures and reporting prevented a formal meta-analysis, and every included trial was judged to have an unclear or high risk of bias. The review therefore did not produce the standardized mean differences sometimes attributed to it.

The frequently cited 2012 Chandrasekhar trial randomized 64 adults with chronic stress to a concentrated root extract or placebo. Participants received 300 mg twice daily for 60 days. Perceived Stress Scale scores declined by 44.0% in the extract group and 5.5% in the placebo group. Mean serum cortisol declined by 27.9% and 7.9%, respectively. This was a small, single-centre trial conducted before the 2020–2025 review period, but it remains important background for later stress studies.

A 2022 systematic review and dose-response meta-analysis included 12 randomized trials with 1,002 participants. The pooled standardized mean difference was −1.55 for anxiety and −1.75 for stress in comparisons with placebo. These apparently large estimates were accompanied by very high statistical heterogeneity—approximately 94% for anxiety and 83% for stress—and the certainty of the evidence was rated low. The pooled numbers therefore do not establish that every formulation will produce an effect of the same magnitude.

One placebo-controlled study published in 2023 randomized 54 adults with mild-to-moderate stress and anxiety; 50 completed the trial. The intervention supplied 500 mg of root extract standardized to 2.5% withanolides plus 5 mg of piperine once daily for 60 days. Scores on the Perceived Stress Scale and Generalized Anxiety Disorder-7 scale were lower than with placebo at day 60, and quality-of-life scores improved. Because this was a proprietary combination containing piperine, its findings do not automatically apply to other ashwagandha extracts.

Cortisol as a Secondary Outcome

Cortisol has been measured as a secondary biomarker in several stress trials. Reductions were reported in the 2012 trial, the 2021 sustained-release root-extract trial and the 2023 root-extract-plus-piperine trial. Cortisol results should be interpreted alongside symptoms and validated clinical scales because sampling time, biological variation and the type of cortisol specimen can influence the measurement. Human trials have not established that direct binding of withanolides to glucocorticoid receptors is the clinical mechanism of action.

Sleep Quality Trials, 2020–2025

Placebo-controlled sleep studies include both people with insomnia and participants reporting non-restorative sleep. Some trials combined questionnaire scores with actigraphy, which estimates sleep and wake periods from movement. The studies used distinct preparations and should be compared by plant part and extract specification as well as by milligram dose.

Publication Participants Preparation and Dose Duration Verified Result
Deshpande et al., 2020 150 adults with non-restorative sleep Root-and-leaf extract, 120 mg/day 6 weeks Subjective sleep-quality improvement was 72% with ashwagandha and 29% with placebo; actigraphy also favored the extract for several sleep measures.
Langade et al., 2021 80 adults; 40 had insomnia Root extract, 300 mg twice daily 8 weeks The insomnia subgroup improved in sleep quality, sleep-onset latency, morning alertness and anxiety measures compared with placebo.
Cheah et al., 2021 meta-analysis 5 trials; pooled n=372 Root extracts at 250–600 mg/day or a root-and-leaf extract at 120 mg/day 6–12 weeks The pooled effect on overall sleep was small but statistically significant; the reported standardized mean difference was −0.59, with I²=62%.

The sleep meta-analysis found larger effects in participants with insomnia, in trials lasting at least eight weeks and in studies using 600 mg/day. These subgroup observations were based on a small collection of trials and should not be interpreted as a universal minimum dose. The 120 mg root-and-leaf extract was substantially more concentrated than ordinary root powder and cannot be compared milligram for milligram with the root extracts.

Cognitive Function, Energy and Mood

A 2021 randomized, double-blind trial enrolled 130 healthy adults with self-reported stress; 125 completed the study. Participants received one 300 mg sustained-release root-extract capsule or placebo daily for 90 days. The ashwagandha group performed better on selected Cambridge Neuropsychological Test Automated Battery measures, including paired-associate recall and total errors. It also had lower perceived-stress and sleep-quality scores, lower serum cortisol and higher psychological well-being scores. The study did not use KSM-66 or a dose of 300 mg twice daily.

A 2024 randomized trial in healthy young adults evaluated a liposomal root-and-leaf extract at 225 mg/day for 30 days, including an assessment after the initial dose. Some measures of memory, attention, vigilance and executive function favored ashwagandha, and participants reported less tension and fatigue. The improvements were not uniform across every cognitive test, and the extract differed substantially from the root-only preparations used in other trials.

Another 2024 prospective placebo-controlled study enrolled 120 adults with self-reported cognitive or energy concerns and administered 600 mg/day of root extract for eight weeks. Improvements were reported in selected measures of episodic memory, working memory, attention, energy and mood. These cognition studies involved different populations, instruments and preparations, so their results do not yet define a standard cognitive-enhancement protocol.

Physical Performance and Strength Outcomes

A 2021 systematic review and Bayesian meta-analysis concluded that ashwagandha groups generally performed better than placebo groups on measures related to strength and power, cardiorespiratory fitness, fatigue and recovery. The underlying trials were small and varied in training status, extract type, dose and outcome selection. Several of the strength studies included in that synthesis were published before 2020.

The often-cited resistance-training trial involving bench-press and leg-extension strength was published in 2015 rather than 2021. A separate 2021 randomized study evaluated cardiorespiratory endurance in healthy athletic adults. A 2024 eight-week placebo-controlled study used 600 mg/day of a standardized root extract in adults performing resistance training and assessed physical endurance and maximal oxygen uptake. Collectively, these studies support continued investigation of exercise outcomes but do not establish equivalence among all ashwagandha products.

Thyroid Outcomes

The randomized trial in 50 participants with subclinical hypothyroidism was published in 2018, not 2020. Participants received 300 mg of root extract twice daily or placebo for eight weeks. The intervention lowered thyroid-stimulating hormone and increased T3 and T4 relative to placebo. These hormonal changes are a reason for clinical caution rather than a general recommendation to treat hypothyroidism with ashwagandha. Case reports of thyrotoxicosis and the possibility of interactions with thyroid-hormone medicines make professional monitoring important.

Regimens Studied Across Clinical Domains

No single “effective ashwagandha dose” can be derived from the trials because extract concentration, plant part and standardization differ. The following table records representative regimens rather than prescribing them. The Ayurvedic Pharmacopoeia’s 3–6 g dose applies to powdered root drug and should remain separate from concentrated-extract dosing.

Clinical Domain Representative Placebo-Controlled Regimens Typical Study Period Interpretive Note
Stress and anxiety 300 mg root extract twice daily; 500 mg root extract with 5 mg piperine once daily; other trials used 240–1,250 mg/day of extract 6–12 weeks Pooled benefits were reported, but product heterogeneity and low-certainty meta-analytic estimates limit dose comparisons.
Sleep 120 mg/day concentrated root-and-leaf extract or 300 mg root extract twice daily 6–8 weeks The pooled sleep effect was small, with larger subgroup effects among participants with insomnia.
Cognition and mood 300 mg/day sustained-release root extract; 225 mg/day liposomal root-and-leaf extract; 600 mg/day root extract 30–90 days Selected outcomes improved, but the trials used different cognitive batteries and populations.
Physical performance Various standardized root extracts, commonly studied alongside structured exercise 8–12 weeks The evidence base combines endurance, strength, recovery and oxygen-uptake outcomes rather than one uniform endpoint.

Trial Quality and Limitations

Most placebo-controlled ashwagandha studies have been small and short, commonly lasting four to twelve weeks. Stress, anxiety and sleep trials frequently rely on participant-reported scales, although some also include cortisol testing, actigraphy or computerized cognitive assessments. Different eligibility criteria and outcome instruments complicate comparisons, while substantial heterogeneity in the stress and sleep meta-analyses reduces confidence in a single pooled effect size.

Several influential trials evaluated named proprietary extracts and disclosed manufacturer employment, commercial sponsorship or fee-for-service funding. Such disclosure does not invalidate a result, but independent replication using clearly characterized products is important. Reporting the botanical name alone is insufficient: a clinically interpretable product description should identify the plant part, extraction method, daily quantity, standardization marker and amount of the standardized constituents.

Ayurvedic Interpretation and Modern Extracts

The official Ayurvedic monograph describes the mature root and records rasāyana, balya, vājīkaraṇa and Vāta-Kapha-alleviating actions. It also lists traditional therapeutic uses including daurbalya, kṣaya, vātaroga, śotha and klaibya. These Ayurvedic categories should be presented in their own clinical framework rather than translated directly into claims about cortisol, generalized anxiety disorder, athletic performance or specific neurotransmitters.

Likewise, a concentrated root-and-leaf capsule standardized to withanolide glycosides is not the same intervention as pharmacopoeial root powder. Modern trial results apply most directly to the extract and population actually tested. Traditional use, pharmacopoeial quality standards and contemporary randomized trials can inform one another, but they do not make all preparations or doses equivalent.

Safety Profile

Ashwagandha was generally well tolerated during trials lasting up to approximately three months. Common reported effects include stomach upset, nausea, loose stools and drowsiness. Long-term safety over many months or years has not been established. Rare cases of acute liver injury have been associated with products containing ashwagandha, although the contents of every implicated product were not independently verified and some contained additional ingredients.

Ashwagandha may alter thyroid function and may interact with thyroid medicines, sedatives, immunosuppressants, antihypertensive drugs and antidiabetes medicines. Specialist advice is appropriate for people with liver disease, thyroid or other endocrine disorders, autoimmune disease, hormone-sensitive prostate cancer or complex medication regimens. Pregnant and breastfeeding individuals should avoid self-prescribing ashwagandha and seek individual guidance from a qualified healthcare professional.

Disclaimer

This article is for educational purposes and is not a diagnosis, prescription or substitute for medical care. Extract specifications and doses used in trials should not be copied without considering medical history, medicines, pregnancy status and product quality. Consult a qualified Ayurvedic practitioner and an appropriate healthcare provider before beginning ashwagandha, particularly when treating persistent anxiety, insomnia, thyroid disease or another diagnosed condition.

Practical monitoring note: When a clinician recommends a supervised trial, record the product name, plant part, extract ratio or standardization, daily dose, timing, baseline symptoms and adverse effects. Stop the product and obtain medical assessment for jaundice, dark urine, marked itching, persistent abdominal symptoms, palpitations, tremor or other significant new symptoms.

References

  1. Ayurvedic Pharmacopoeia of India
  2. NIH Office of Dietary Supplements
  3. An alternative treatment for anxiety: a systematic review of human trial results reported for the Ayurvedic herb ashwagandha (Withania somnifera) (2014), PubMed
  4. A prospective, randomized double-blind, placebo-controlled study of safety and efficacy of a high-concentration full-spectrum extract of ashwagandha root in reducing stress and anxiety in adults (2012), PubMed Central
  5. Does Ashwagandha supplementation have a beneficial effect on the management of anxiety and stress? A systematic review and meta-analysis of randomized controlled trials (2022), PubMed
  6. A standardized Ashwagandha root extract alleviates stress, anxiety, and improves quality of life in healthy adults by modulating stress hormones: Results from a randomized, double-blind, placebo-controlled study (2023), PubMed Central
  7. A standardized Ashwagandha root extract alleviates stress, anxiety, and improves quality of life in healthy adults by modulating stress hormones: Results from a randomized, double-blind, placebo-controlled study (2023), PubMed
  8. A randomized, double blind, placebo controlled study to evaluate the effects of ashwagandha (Withania somnifera) extract on sleep quality in healthy adults (2020), PubMed
  9. Clinical evaluation of the pharmacological impact of ashwagandha root extract on sleep in healthy volunteers and insomnia patients: A double-blind, randomized, parallel-group, placebo-controlled study (2021), PubMed
  10. Journals (journals.plos.org)
  11. Efficacy and Safety of Ashwagandha Root Extract on Cognitive Functions in Healthy, Stressed Adults: A Randomized, Double-Blind, Placebo-Controlled Study (2021), PubMed
  12. Efficacy and Safety of Ashwagandha Root Extract on Cognitive Functions in Healthy, Stressed Adults: A Randomized, Double-Blind, Placebo-Controlled Study (2021), PubMed Central
  13. Acute and Repeated Ashwagandha Supplementation Improves Markers of Cognitive Function and Mood (2024), PubMed Central
  14. Safety and Efficacy of Ashwagandha Root Extract on Cognition, Energy and Mood Problems in Adults: Prospective, Randomized, Placebo-Controlled Study (2026), PubMed
  15. Effects of Ashwagandha (Withania somnifera) on Physical Performance: Systematic Review and Bayesian Meta-Analysis (2021), PubMed Central
  16. Examining the effect of Withania somnifera supplementation on muscle strength and recovery: a randomized controlled trial (2015), PubMed
  17. A double-blind, randomized, placebo-controlled trial on the effect of Ashwagandha (Withania somnifera dunal.) root extract in improving cardiorespiratory endurance and recovery in healthy athletic adults (2021), PubMed
  18. Effects of Ashwagandha ( Withania somnifera) standardized root extract on physical endurance and VO (2max) in healthy adults performing resistance training: An eight-week, prospective, randomized, double-blind, placebo-controlled study (2023), PubMed Central
  19. Efficacy and Safety of Ashwagandha Root Extract in Subclinical Hypothyroid Patients: A Double-Blind, Randomized Placebo-Controlled Trial (2018), PubMed
Tags: anti-aging CRISPR Gene Editing longevity Rasayana telomeres